Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Newly-Tested Tool Predicts PICC-DVT Risk

J Thromb Haemost; ePub 2017 Sep 13; Chopra, et al

A newly-tested tool can estimate the risk of deep vein thrombosis (DVT) in patients with peripherally inserted central catheters (PICCs), according to a study involving more than 23,000 individuals. Participants with upper extremity DVT were divided into 4 risk classes. The Michigan PICC-DVT Risk Score was then tested and validated to determine factors linked with PICC-DVT. Among the results:

  • 2% of patients developed PICC-DVT.
  • Risk factors included DVT history, multi-lumen PICC, active cancer, presence of another central venous catheter, and white blood cell count >12,000.
  • Thrombosis rates were 0.9% for class I, 1.6% for class II, 2.7% for class III, and 4.7% for class IV.
  • Predicted probabilities were 0.9%, 1.5%, 2.6%, and 4.5%, respectively.
  • Patients in class II were 50% more likely to develop PICC-DVT than those in class I.
  • Patients in classes III and IV were nearly 3 and >5 times more likely, respectively.

Citation:

Chopra V, Kaatz S, Conlon A, et al. The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis. [Published online ahead of print September 13, 2017]. J Thromb Haemost. doi:10.1111/jth.13794.

This Week's Must Reads

Monetary support affects select prescribing, Mitchell AP et al. JAMA Intern Med. 2018 Apr 9. doi: 0.1001/jamainternmed.2018.0776

Best TKI options in ALL, Jabbour E et al. Clin Lymphoma Myeloma Leuk. 2018 18(4):257-65

2 approaches to diagnosing heparin-induced thrombocytopenia, Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103

Blinatumomab eliminates residual B-cell ALL, Gökbuget N et al. Blood. 2018 Apr 5;131(14):1522-31.

Aryl hydrocarbon receptor antagonist boosts cord blood engraftment, Wagner J et al. 2018 Bone Marrow Transplant Tandem Meetings, Abstract 4.

Must Reads in Thrombosis

2 approaches to diagnosing heparin-induced thrombocytopenia, Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103

VTE prophylaxis unaddressed in acutely ill patients, Amin A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 51.

Warfarin users take 10 other drugs on average, Jacobson A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018. Poster 2

LVADs as destination therapy, Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

Guideline on Preventing VTE in Pediatric Cancer, J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al